Navigation Links
IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
Date:7/29/2010

MOUNTAIN VIEW, Calif., July 29 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.

The Adjustable Laser Probe speeds up treatments by allowing continuous adjustment of the optical fiber over a wide range of angles for full coverage of the peripheral retina without requiring removal and reinsertion of the probe from the eye.

"We continue to focus on ways to increase the value of our consumable instrumentation line by offering novel and creative product solutions to our ophthalmic customers which in turn will help us grow our business," stated Theodore A. Boutacoff, President and CEO, "and to reconfirm our corporate position as a leader in our market."

"The issuance of this patent is valuable to IRIDEX because it helps us maintain the differentiation of our vitreoretinal product line from those of our competitors, and we plan to capitalize on the leverage afforded by this new patent by expanding this product line in the near future."

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's ability to increase the value of its consumable products, grow its business, differentiate its products and increase its product offerings in the near future.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010 which was filed with the Securities and Exchange Commission and in our Quarterly Report on Form 10-Q for the fiscal quarter ended April 3, 2010. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
2. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
3. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
4. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
5. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
6. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
7. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
8. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
9. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
10. BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
11. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... July 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... its second quarter 2017 operating results on Monday, August ... to follow at 5:00 p.m. ET. ... to a live broadcast of the conference call by ... participant code 51641230 approximately 15 minutes prior to the ...
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/14/2017)... VEGAS , July 13, 2017 It should ... United States is in the midst of a ... Control , since 1999, the number of overdose deaths from ... "resulting in over half a million dead from 2001 to ... codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 2017 , ... Patients with missing teeth now have the ... from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and prosthodontist who ... dental implants in Longview, TX. , During traditional dental implant ...
(Date:7/27/2017)... ... 27, 2017 , ... TransPanel Volume 4 is a collection of animating panel ... exclusive features transitions that contain between 2 and 6 animated panels. Change the direction ... menus. TransPanel Volume 4 makes editing easy in Final Cut Pro X. , TransPanel ...
(Date:7/27/2017)... Clara, CA (PRWEB) , ... July 27, 2017 ... ... announces the addition of a secure cloud-based polysomnography (PSG) distributed scoring solution to ... support accelerated diagnostics and sleep care management. The speed and functionality of scoring ...
(Date:7/27/2017)... ... 2017 , ... SSCI, a division of Albany Molecular Research, ... representing a milestone achievement. , As an industry-leading provider of ... served as expert and fact witnesses to assist our clients to perform infringement ...
(Date:7/27/2017)... ... ... Angeles leg of the US movie premier of the Man in the Camo Jacket will ... Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the LA Live ... musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer and inspiring ...
Breaking Medicine News(10 mins):